What happened with CSTL today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Castle Biosciences analyzes patient tissue in its own laboratories and sends clinicians reports to help them assess disease and choose care. Its tests measure biological signals and use algorithms to interpret them. Skin-cancer tests generate most revenue, while TissueCypher is an important additional source. DecisionDx-Melanoma assesses the risk of melanoma spreading or returning; TissueCypher assesses the risk of Barrett’s esophagus progressing to esophageal cancer. These tests and DecisionDx-SCC, for high-risk skin squamous cell carcinoma, have supplied the bulk of revenue.
Clinicians order the tests, but Medicare and commercial health insurers provide most of the payment. Revenue depends both on clinicians using the tests and on insurers agreeing to cover and reimburse them; an agreed payment rate alone does not guarantee payment. Medicare supplies a substantial share of revenue, and one commercial insurer also accounts for a meaningful share. Medicare coverage for DecisionDx-SCC has ended, limiting reimbursement for that test.
Castle performs testing at its Phoenix and Pittsburgh laboratories rather than at local pathology practices. It must maintain laboratory certification and accreditation to operate and remain eligible to bill government healthcare programs and commercial insurers.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Beyond clinician adoption and continued Medicare coverage, Castle depends on sole-source test materials from Thermo Fisher Scientific and Promega.
Veracyte and Castle both need clinical evidence and insurance coverage to turn genomic tests into revenue: Veracyte sells prostate and thyroid tests, while Castle sells tissue-based cancer-risk tests. Watch evidence and reimbursement developments for Veracyte’s main revenue earners, Decipher Prostate and Afirma, as a comparison for Castle’s adoption hurdles.
Lucid Diagnostics and Castle address different steps in esophageal cancer prevention: Lucid’s EsoGuard detects precancer, while Castle’s TissueCypher predicts progression in Barrett’s esophagus. Lucid’s reliance to date on out-of-network commercial insurance payments for most revenue makes EsoGuard coverage news worth watching alongside TissueCypher adoption, rather than treating the tests as identical rivals.
Biodesix offers a comparison for Castle’s ability to sell proprietary tests that help specialists make cancer-care decisions: its blood tests assess lung risk and guide treatment, while Castle analyzes tissue. Watch Biodesix’s lung Diagnostic Tests revenue rather than its separate testing and consulting services for research customers.
MDxHealth and Castle both sell molecular tests to inform specialist cancer care, but MDxHealth serves prostate patients while Castle’s skin-cancer tests support risk assessment and diagnosis. Adoption of MDxHealth’s Exo mdx, Confirm mdx and GPS mdx across risk assessment, diagnosis and treatment decisions offers a comparison for how Castle’s tests fit into specialist practice.
CareDx and Castle are both sensitive to Medicare coverage decisions for molecular tests: CareDx sells transplant tests, while Castle sells cancer-risk tests. CareDx’s coverage news offers a comparison for Castle’s reimbursement exposure, despite the different specialists they serve.
Natera and Castle both benefit from broader clinical use of molecular cancer tests, although Natera’s blood tests monitor cancer and guide therapy while Castle’s tests predict risk and guide management. Watch uptake of Natera’s oncology tests sold directly and through laboratory partners as a comparison for demand, not its women’s-health or organ-health offerings.
Guardant Health and Castle both collect Medicare and commercial-insurer payments for molecular cancer tests used in clinical care, although their main testing applications differ. Guardant’s oncology testing revenue offers a closer comparison for Castle’s adoption and reimbursement prospects than its biopharma services or technology licensing.
Castle depends on QIAGEN for certain sole-source test materials, so supply or quality failures could disrupt its diagnostic work; QIAGEN sells consumables and equipment for extracting and analyzing molecular information from samples. Watch availability and quality of those materials: Castle has alternative sourcing strategies and has reported no sourcing-related interruption, but cannot guarantee substitutes will be available when needed.
CareDx, Inc. earningsCDNA
CareDx’s report may show how Medicare coverage and payment for molecular tests are changing, giving Castle Biosciences a reference point for the reimbursement risk on its cancer tests.
Look for explicit updates on Medicare coverage or payment, rather than treating CareDx’s total revenue as a proxy for Castle Biosciences. Better coverage or payment terms would be a supportive signal for the reimbursement environment, but transplant tests differ from Castle’s cancer tests and do not establish their coverage. Tighter terms would show that reimbursement risk remains; Castle’s tests still depend on their own coverage decisions.
QIAGEN N.V. earningsQGEN
If QIAGEN’s report flags supply or quality problems with materials Castle Biosciences buys, it would point to a possible disruption risk for Castle’s testing labs.
Watch for a specific QIAGEN disclosure of supply or quality problems involving materials Castle buys. If such a problem affects those materials and Castle cannot use substitutes, lab testing and reports could be delayed. If QIAGEN reports no problem, that is only an absence of a warning, not confirmation that Castle’s supply is secure.
Castle Biosciences, Inc. earningsThis company
Castle Biosciences sells tests to insurers, and this report will show whether growth in non-dermatology tests is making up for the revenue and margin pressure after Medicare stopped covering DecisionDx-SCC.
Read revenue and report volumes for dermatologic and non-dermatologic tests alongside gross margin, paying particular attention to growth in non-dermatologic tests such as TissueCypher and the price pressure on DecisionDx-SCC. Rising non-dermatologic revenue and report volumes with steadier gross margin would mean the newer business is filling the gap without costs consuming the growth. If report volumes rise but revenue or margin weakens, reimbursement prices or testing costs are still offsetting demand.
Guardant Health, Inc. earningsGH
Guardant Health’s oncology-testing revenue offers a read on adoption and reimbursement for cancer molecular tests, a point of comparison for Castle Biosciences’ tissue tests.
Focus on Guardant Health’s oncology-testing revenue, not its biopharma services or technology licensing. Growth would show that demand and payment are supporting its cancer-testing business, an indirect positive signal for Castle. Flat or falling revenue could point to adoption or reimbursement headwinds. Guardant’s blood tests serve different uses from Castle’s tissue tests, so this figure alone cannot settle demand for Castle.
